Posts
- OmniComm Systems Signs Five-Year, Multi-Million Dollar TrialMaster EDC Agreement with CROMSOURCE
- CROMSOURCE Expands Operational Footprint and Management Team
- CROMSOURCE Expansion Medical Services CMO
- CROMSOURCE Continues Strong US Growth with Multiple New Business Awards
- CROMSOURCE Celebrates its 20th Anniversary
- CROMSOURCE Regulatory Team to Present at TOPRA’s Clinical Evaluation of Medical Devices Masterclass
- CROMSOURCE Offers Clients One Trial One Price™ Guarantee
- CROMSOURCE Unveils New TalentSource Life Sciences Department Logo
- CROMSOURCE Appoints Director of Regulatory Services and Expands Regulatory Operations
- Penta and CROMSOURCE Announce their Partnership to Improve Paediatric Drug Development
- CROMSOURCE Continues US Growth with New Office in Research Triangle Park
- CROMSOURCE Consolidates its Hybrid Services Model
- CROMSOURCE announces a significant milestone in digital management of its projects in cooperation with TECHORIZON
- CROMSOURCE Announces Launch of COVID-19 Clinical Trial
- CROMSOURCE Consolidates Strategic Site Support Service
- CROMSOURCE Announces Appointment of Kris O’Brien as Global Head of TalentSource Life Sciences
- Dialco Medical Inc. Engages CROMSOURCE as CRO Partner for DIMI IDE Trial
- Stayble Therapeutics receives approval to start Phase Ib clinical trial with STA363 for the treatment of herniated discs
- ClinChoice Acquires CROMSOURCE, Expanding its Global Presence
- CROMSOURCE Regulatory Newsletter January – March 2023
- First Patient Enrolled in Stayble Therapeutics’ Phase 1b Clinical Study in Herniated Discs
